Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CUP

regeneron headquarters

FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19

In Europe, the EMA will review a Marketing Authorisation Application for the antibody cocktail

- PMLiVE

Fishawack Health appoints new CEO, Jonathan Koch

Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

Avalere Health

- PMLiVE

Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role

Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.

Avalere Health

- PMLiVE

bluebird bio gears up for split

The company has filled its coffers with $75m in new funding and hired new leaders to support its split into two separate companies, bluebird bio and 2seventy bio

- PMLiVE

Future of MHRA uncertain amid Brexit-fuelled shake up

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

- PMLiVE

CureVac to push ahead with first- and second-generation COVID-19 vaccines

The biotech will seek EMA approval for first-generation jab while trials are due to start for second-generation jabs in Q4

- PMLiVE

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand

The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...

Impetus Digital

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership

- PMLiVE

EMA authorises Pfizer/BioNTech’s COVID-19 vaccine for children aged 12 to 15

Clinical trial data recently showed that the vaccine is safe and effective in individuals in this age group

- PMLiVE

Rare diseases: why they can be so difficult to identify

Symptoms shared with more common diagnoses can make it more difficult to spot underlying rare diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links